INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Grant or awardVerified data

Lenz Robert A. reported LBRX

Director · LB PHARMACEUTICALS INC · LB PHARMACEUTICALS INC — Stock Option (Right to Buy)

Side
A
Value
—
Shares
20.0K
Price
—
Executed
Mar 6, 2026
Disclosed
Mar 10, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Mar 6 executedMar 10, 2026 disclosed

LBRX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · LBRX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    KG
    Kozauer Susan GaniChief Medical Officer
    LBRXLB PHARMACEUTICALS INC
    Grant or award
    		A—
    200.0K sh
    		Oct 9, 2026Oct 13, 2026
    traded Oct 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    MM
    Miller Joseph MChief Financial Officer
    LBRXLB PHARMACEUTICALS INC
    Grant or award
    		A—
    200.0K sh
    		Oct 9, 2026Oct 13, 2026
    traded Oct 9, 2026
    		+4dSEC FORM 4

    Evidence

    9
    LR
    Luse RebeccaDirector
    LBRXLB PHARMACEUTICALS INC
    Grant or award
    		A—
    10.0K sh
    		Jun 3, 2026Jun 5, 2026
    traded Jun 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    LA
    Lenz Robert A.Director
    LBRXLB PHARMACEUTICALS INC
    Grant or award
    		A—
    12.5K sh
    		Jun 3, 2026Jun 5, 2026
    traded Jun 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    PK
    Pai Panandiker Kaya KamleshChief Commercial Officer
    LBRXLB PHARMACEUTICALS INC
    Grant or award
    		A—
    195.0K sh
    		Dec 10, 2025Dec 11, 2025
    traded Dec 10, 2025
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001992908-26-000007
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 6, 2026
    Published
    Mar 10, 2026
    Ingested by INSIDER
    Nov 5, 04:12 UTC
    Last re-read
    Nov 5, 04:12 UTC

    Extracted facts

    Filer
    Lenz Robert A.
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    LB PHARMACEUTICALS INC — Stock Option (Right to Buy)
    Ticker
    LBRX
    Shares
    20.0K
    Price per share
    $0
    Execution date (reported)
    Mar 6, 2026
    Owned after transaction
    20.0K shares
    Days from execution to publication
    4

    What this establishes

    Lenz Robert A. filed this Form 4 reporting a grant or award of LBRX on Mar 6, 2026. It became public on Mar 10, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Lenz Robert A.cik:0001992908
    Issuer
    LB PHARMACEUTICALS INCcik:0001691082

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.